5 stories
Published the day after Foundayo's FDA approval, a new indirect comparison found oral semaglutide may produce greater weight loss than orforglipron with fewer GI discontinuations.
With one in ten American adults already on GLP-1 drugs, next-generation medications including Foundayo and retatrutide could reach the ~25% of patients who don't respond to current GLP-1 monotherapies.
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.
The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable semaglutide or tirzepatide to oral orforglipron maintained their weight loss.
New research finds approximately 25% of weight lost persists after GLP-1 discontinuation. Trajectories were similar across semaglutide, liraglutide, and tirzepatide.